All News
Preview of EULAR 2019 Abstracts
EULAR 2019 begins today in Madrid and features over 2000 presentations. After an initial review of titles and abstracts, I’ve compiled a hit list of presentations of interest to me and hopefully other practicing rheumatologists.
Read Article
No point on repeating ANA testing PPV 0.01 according to this abstract by Yeo et al. #EULAR2019 #Rheumatology @RheumNow https://t.co/kX0angBvqd
Sebastian C Rodriguez-García sdlcrodriguez ( View Tweet)
Full house in Jaki and beyond session. S Cohen presented fenebrutinib a BTK inhibitor at doses including 200 mg bid is in TNFI-IR or Mtx-IR active pts with RA in a Phase II RCT. 12 week data were similar to adalimumab. New pathway for RA Rx maybe #OP0025 https://t.co/avLSopLju6
Janet Pope Janetbirdope ( View Tweet)
Difficult to use existing “borrowed” conventional measures or essdai to measure change in the joint domain (most commonly affected) in abatacept study on primary Sjogren #eular2019 @RheumNow
Alberta Hoi tuna0sashimi ( View Tweet)
Disappointing @tuna0sashimi: BMS abatacept 125mg wkly in Sjogren: essdai >=5 SSA+ primarily outcome mean change in essdai. Day 169 onwards open label. Negative study using these endpoints but some positive effect on serum IgG and complements. #eular2019 @RheumNow
Dr Irwin Lim _connectedcare ( View Tweet)
Fantastic talk by Georgios Filippou highlighting how we can use US to help us differentiate DDx and clinical phenotypes. #eular2019 @RheumNow https://t.co/hxKqrziDSN
Alberta Hoi tuna0sashimi ( View Tweet)
Empathic communication can help close the gap with patients - this is a learned skill - we need to work on it as a profession #empathy @HelenRiessMD @vmontori @JohnDavisIII @RheumNow @HealioRheum https://t.co/1pwn56o9lc
Leonard Calabrese LCalabreseDO ( View Tweet)
Romosozumab has dual effect: bone-forming AND preventing resorption. Hitting hard with this early in #osteoporosis reduces fracture risk later when on denosumab, compared to those receiving placebo prior. Similar results when patients switch to alendronate. @RheumNow #EULAR2019 https://t.co/ZSQAxSUnv9
Mrinalini Dey DrMiniDey ( View Tweet)
With OA therapeutics, there’s disease, and then there’s illness. Any disease modifying effect that might be there can get drowned out by fibromyalgia... Data on lorecivivint in Marc Hochberg’s anabolic DMOAD overview SP0013 #EULAR2019 @RheumNow https://t.co/GALk9hs8KB
David Liew drdavidliew ( View Tweet)
Filippou shows us US vs synovial exam of crystal: US more sensitive but less specific than synovial aspirate. Beware the double contour sign in CPPD mimicking gout but calcification moves discordant with the bone. #eular2019 @RheumNow https://t.co/W8pftdfa0I
Alberta Hoi tuna0sashimi ( View Tweet)
OA is multifactorial. So why do we expect a silver bullet therapeutic solution?
Rik Lories on manipulating signaling pathways for treating OA #EULAR2019 SP0013 @RheumNow https://t.co/0g2ZLT4XfN
David Liew drdavidliew ( View Tweet)
@benjaminsutu @dr_rachelblack @tuna0sashimi @RheumNow You want puns? We got puns https://t.co/MxGSOE9BI7
David Liew drdavidliew ( View Tweet)
Do NSAIDs work in Axial Spondyloarthritis? YES! The all work but none is better or safer than the others #EULAR 2019 abstr SP0003 https://t.co/z2Dp8Cf2PV
Dr. John Cush RheumNow ( View Tweet)
CPPD together with syphilis and TB as the great mimicker in rheumatology #eular2019 @RheumNow
Alberta Hoi tuna0sashimi ( View Tweet)
The very first WIN and HOT session is about to begin. Join us as we explore ‘New Avenues of OA & Osteoporosis Management’ in Hall 6 at 14.15.(CEST). See it on the move on @YouTubeTV #EULARLIVE: https://t.co/LojAOi4cAZ https://t.co/eoggidKWZ9
Links:
EULAR | The European League Against Rheumatism eular_org ( View Tweet)
Acetaminophen had more diarrhea and transaminitis than placebo in RCTS. In nonrandomized studies there were 1.4 times more UGI bleeds but likely channeling bias. Ok for CV events in RCTs; mixed results in uncontrolled studies for CV and renal. @RheumNow #EULAR2019 0P0019-HPR https://t.co/Y8f87jnxbR
Janet Pope Janetbirdope ( View Tweet)
Good news for scleroderma lung disease. Abstract OP0017 shows less decline in SSc ILD with nintedanib v placebo. Half on MMF in both groups. Less decline if on MMF but still 40% reduction in active v placebo in both subsets and combination seemed safe. @RheumNow #EULAR2019 https://t.co/1CJ4sggZsj
Janet Pope Janetbirdope ( View Tweet)
Go Ai Li! Winner of clinical science abstract awards @Monash_FMNHS @RheumNow #eular2019 https://t.co/7cLYREEAlY
Alberta Hoi tuna0sashimi ( View Tweet)
Looking forward to joining Jack and the rest of the team in reporting for @RheumNow from #EULAR2019 in sunny Madrid this week! https://t.co/WLhaq2KtsR https://t.co/BJGxfDKfcA
David Liew drdavidliew ( View Tweet)
Plenary session of JIA post TNFI failure OP0016 from 2 UK registries by Kearsley-Fleet shows no difference in 151 kids who go to 2nd TNFi vs switch to different biologic for response and retention. Either is ok. @RheumNow #EULAR2019
Janet Pope Janetbirdope ( View Tweet)